allogeneic BMT in CR1 and developed EBV-LPD 1.5 months later. Attempts to eradicate the monoclonally proliferating LPD using chemotherapy (VP16/dexamethasone) A patient with AML (FAB M4Eo) developed EBV-LPD 1.5 months after allogeneic BMT from his one locusfollowed by EBV-CTL infusions were unsuccessful. In addition, our patient developed EBV-LPD after receiving mismatched mother, the diagnosis being confirmed on day +82. Attempts to eradicate the monoclonally prolimarrow from his one locus-mismatched mother, and not from an unrelated donor or a haploidentical donor utilizing ferating LPD using chemotherapy (VP16/dexamethasone) followed by two doses of EBV-specific CTL T-lymphocyte depletion which is unusual, because there are very few EBV-LPD cases who have received marrow from and one dose of unstimulated donor leukocytes were not successful. We assume delay of infusions (day +100, one locus-mismatched related donors. Irradiated lymphoblastic cells prepared from 10 ml of +107) and insufficient CTL cell doses (total 9.2 × 10 6 ) may have been responsible for the poor outcome in heparinized recipient peripheral blood (PB) were used as targets. One hundred milliliters of heparinized donor PB this case.
virus-associated lymphoproliferative disorder; cytotoxic T-lymphocyte 4 Gy irradiated recipient target cells were mixed in a 2-ml well using all 24 wells in the plate. The mixture was harvested after subculture for 6 days and restimulated under the following condition; effector cells 5 × 10 5 , irradiated EBV-LPD is one of the most troublesome complications target cells 1.5 × 10 5 and IL-2 20 Japan Reference Unit/ml after transplantation. It has been reported mostly following in a 2-ml well cultured for 4 days. Two transfusions were organ transplantation, but it has also been documented in given over a period of 2 weeks using similarly prepared patients receiving bone marrow transplantation (BMT), donor cells and one dose of unstimulated donor lymphoparticularly from unrelated donors. 1 Symptoms of EBVcytes. Cell counts are described later. A lymphoblastic cell LPD include persistent fever, lymphadenopathy and hepaline (LCL) was also established in vitro 30 days from day tosplenomegaly. 2 However, prediction and early detection +90 recipient PB; unfortunately, this was after the diagnosis of EBV-LPD are not necessarily easy and once the disease was confirmed. develops, the prognosis of patients is very poor. 1 EBV is believed to be controlled in the normal host by virus-specific cytotoxic T-lymphocytes (CTL), which lyze Case report EBV-infected B cells. CTL is thought to be essential in maintaining control of latently EBV-infected cells. Unsep-
The patient was an 11-year-old boy diagnosed with AML arated leukocytes from EBV-seropositive donors, 3 and (FAB M4Eo) in June 1994. He presented with a WBC of donor lymphocytes 4 have been used to treat EBV-associa-164 700/l (blasts 96%), Hb 6.7 g/dl, platelets 26 000/l. ted lymphoproliferation including immunoblastic lymBlasts were present in the cerebrospinal fluid (cell count phomas in post-bone marrow transplants as sources of 11/3, blast 44%), associated with a ringed, high intensity EBV-specific CTL. More recently, Rooney et al 5 docuarea (leukemia-associated hemorrhagic lesion) in the right mented the effectiveness of infused EBV-specific CTL preparieto-occipital region on CT scan. Bone marrow karypared from donor leukocytes for patients with EBV-LPD.
otype revealed 46,XY,inv(16)(p13q22 8 /kg bone marrow cells were infused and for GVHD prophylaxis, short-term MTX/CsA was given.
The immediate post-BMT course was uneventful, and on day +12, the WBC recovered to above 1000/l. However, around day +30 when the CsA was switched from continuous infusion to oral administration (3 mg/kg/day) and mPSL was tapered off, the patient developed fever, diarrhea and vomiting associated with severe abdominal pain and a sharp rise in CRP (up to 12.5 mg/dl). Blood-stained loose to continuous infusion were used to control this acute GVHD episode; however, because of the incomplete response, FK506 (0.1 mg/kg/day, continuous infusion, folmixed cell type) with positive EBER by in situ hybridizlowed by 0.2 mg/kg/day orally) was introduced from day ation and with IgH chain rearrangement. The patient was +40. With FK506 and intermittent mPSL treatment the treated with VP16 (150 mg/m 2 /day × 5 days, i.v.) and patient gradually recovered.
dexamethasone from day +90, which promptly reduced the On day +54, a lymph node (1 cm diameter) was noted lymphocyte count ( Figure 1 ), but which was followed by in the right cervical area, an unusual finding with intensive hyperbilirubinemia. Around day +95, the patient developed immunosuppression. Around this time the serum IgG was massive bilateral pleural effusions and ascites. As shown 1136 mg/dl. On day +60, a gradual but steady increase of in Figure 2 , small non-blastic but abnormal lymphocytes the lymphocyte count (from 300/l to 13 350/l) was noted were increased in the blood and in pleural fluid/ascites. The associated with an increase of lactate dehydrogenase (LDH patient received two transfusions of EBV-CTL (8.2 × 10 6 from 480 IU/l to 1140 IU/l) and serum IgG (up to on day +100, 1.0 × 10 6 on day +107) and unstimulated 3645 mg/dl) which continued up to day +90. Cervical donor lymphocytes (1.26 × 10 7 on day +117) without lymph nodes were palpable on both sides. Serum Ig studies recovery of normal lymphocytes or any beneficial effect. demonstrated a sharp peak of M-protein (IgG-kappa). CytoHe died on day +118. genetic analyses revealed only 46,XX on days +75, +89, suggesting proliferating B cells (circulating lymphocytes were T cell 6% and B cell 92%) to be of donor origin. Discussion Abdominal CT scan and endoscopic examination revealed a large mass in the ascending colon. Biopsy per-EBV-LPD develops in up to 30% of recipients of HLAformed on day +82 confirmed B cell lymphoma (diffuse, mismatched or HLA-matched, unrelated donor bone marrow transplant recipients. Time intervals from the BMT occurs between 30 and 77 days of BMT. Most of the cases up clinical signs and symptoms suggestive of LPD. Blood samples must also be collected for evaluation. have rapidly progressive symptoms. Times from onset of symptoms to death ranged from 2 to 45 days (median 11
In terms of treatment, the big questions are when therapy should be initiated, and what kind of treatment will be days). 6 Our patient received his BMT not from an unrelated donor but from his one locus-mismatched mother and effective to stop the development of a full-blown EBV-LPD, since the full-blown form is often resistant to therapy. developed LPD at 1.5 months (day +54) from BMT, which was compatible with the early onset type. The diagnosis Previous therapeutic attempts have included acyclovir (ACV), intravenous gammaglobulin, corticosteroids, interwas confirmed much later, on day +82 by immunohistological study of the biopsied colon mass, which was further feron-gamma, ACV combined with interferon-alpha, 8, 9 or cytotoxic drugs, 10,11 CD21 and CD24 anti-B cell monoconfirmed to be EBER-positive by in situ hybridization. Although the patient had a high titer for EADR-IgG (×40) clonal antibodies 12 and CTL. 3, 4 It has been emphasized that EBV-LPD should be diagnosed early and treated appropribefore BMT measurement of antiviral antibody responses post-BMT was not informative, probably because of an ately. If it is sufficiently early, a reduction in immunosuppressive therapy with or without chemotherapy and/or radiimpaired endogeneous humoral response.
The most important issue is how soon we can predict the ation could be beneficial. 13, 14 In addition to the above treatments low-dose cytosine arabinoside reported for its occurrence of early onset-type EBV-LPD during the post-BMT course. In our previous report of polyclonal postusefulness in patients with end-stage lymphoproliferative disorders may be worth giving in the future.
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BMT EBV-LPD, 7 the patient demonstrated the first clinical symptoms 1 month, and hyper-gamma globulinemia with Our patient received ACV (5 mg/kg × 3 days) from day −3 for his entire post-BMT course, which was thought to M-protein around 1.5 months after BMT. In this case, a routine check of M-protein by serum electrophoresis was have no effect on development of the EBV-LPD. Withdrawal of FK506 was ineffective, and we did not use alphanot carried out, and the presence of cervical adenopathy on day +54 did not attract attention as possible EBV-LPD; interferon which is possibly effective against EBV-LPD in recipients of solid organ grafts. The only chemotherapy we however, in retrospect this was the initial sign of EBV-LPD. We should also have suspected LPD earlier from the employed was a VP16/dexamethasone combination, which rapidly decreased circulating lymphocytes. However, large gradual and steady increase in lymphocyte count starting at 2 months, and that of the serum IgG between 2-3 months numbers of lymphocytes remained in the pleural fluid and ascites despite chemotherapy-induced lymphocytopenia following BMT, despite the fact that the patient had been receiving treatment with immunosuppressants, including ( Figure 1) . Following the chemotherapy, we infused EBVspecific CTL prepared from donor leukocytes cocultured FK506. The morphological characteristics of the B lymphocytes (Figure 2 ) in the peripheral blood should have with irradiated recipient EBV-infected lymphoblasts, which showed no beneficial effect. At the time of CTL infusion, attracted prompt attention. Establishing the spontaneous EBV B cell line was delayed and it took 30 days from the GVHD was not active and the patient was off FK506; however, it was soon after administration of the day +90 PB cells, so that this information was not of use for making a prompt diagnosis. From these experiences, VP16/dexamethasone and the patient was still immunosuppressed ( Figure 1 ). Possibly, CTLs should have been we emphasize that EBV-LPD may develop early, probably around day +30 to +50 post-BMT, and should be suspected infused before introducing chemotherapy in this patient. According to the therapeutic results of Rooney et al, 2 in any patient with swelling of the lymph nodes, a steady increase in lymphocyte counts, an increase in serum IgG or CTLs were very effective for two patients with signs of EBV reactivation without overt lymphoproliferation, and emergence of an M-protein peak on serum electrophoresis.
Rooney et al 2 reported two useful methods for predicting for one with immunoblastic lymphoma, and effected resolution. The last case received four CTL infusions (two patients at high risk for EBV-LPD. One was observation of spontaneous outgrowth of transformed B lymphocytes 1 × 10 7 /m 2 and two 5 × 10 7 /m 2 ). The published data suggest that 0.8-2 × 10 6 /kg body weight of donor T lymphocytes, ex vivo, occurring in routine samples and preceding the clinical diagnosis by 0-7 weeks. In addition, transformed or 1-10 × 10 7 /m 2 EBV-specific CTL were found to be useful, but not in our case. The reason why our preparations cells were evident within 14-24 days of culture; however, attempts to establish a spontaneously growing cell line must of EBV-specific CTL were not beneficial is probably due to the delay between presentation (day +54) and confirstart early, or as in our case, it is not useful for early diagnosis. Second was the quantitative detection of EBV-DNA mation of diagnosis (day +90). There was then a further delay in CTL transfusion (day +100) and only small doses by a PCR method. Rooney et al 2 concluded that both the outgrowth of transformed B lymphocytes ex vivo (100% of CTL (9.2 × 10 6 = 7.6 × 10 6 /m 2 ) were administered although the efficacy of relatively low numbers of donor correlation) and the detection of EBV-DNA by a PCR method (80% correlation) showed a statistically significant leukocytes (Ͻ10 6 /kg) has been previously suggested by Mackinnon et al. 16 The very rapid clinical course and association with the histopathological diagnosis of EBV-LPD. The high level of viral DNA is thought to indicate delayed diagnosis of EBV-LPD may have been responsible for our treatment failure. Attempts to control EBV-LPD in impaired T cell immunity which permits uncontrolled viral replication. It was proposed that blood samples be examfuture bone marrow transplant recipients should be made by prompt diagnosis (Table 1) followed by infusion of EBVined on day +30 and thereafter. We agree that the critical period seems to be very narrow, between day +30 and +50, specific CTL which must be prepared in a timely fashion and in sufficient doses. during which time careful observation is necessary to pick therapy for lymphoproliferative disorders developing in two
